GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocytogen Pharmaceuticals (Beijing) Co Ltd (FRA:I54) » Definitions » Total Receivables

Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) Total Receivables : €30.7 Mil (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Biocytogen Pharmaceuticals (Beijing) Co Total Receivables?

Biocytogen Pharmaceuticals (Beijing) Co's Total Receivables for the quarter that ended in Dec. 2024 was €30.7 Mil.


Biocytogen Pharmaceuticals (Beijing) Co Total Receivables Historical Data

The historical data trend for Biocytogen Pharmaceuticals (Beijing) Co's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocytogen Pharmaceuticals (Beijing) Co Total Receivables Chart

Biocytogen Pharmaceuticals (Beijing) Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Total Receivables
8.56 14.48 14.68 18.37 30.75

Biocytogen Pharmaceuticals (Beijing) Co Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Total Receivables Get a 7-Day Free Trial Premium Member Only 14.68 15.07 18.37 23.91 30.75

Biocytogen Pharmaceuticals (Beijing) Co Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables


Biocytogen Pharmaceuticals (Beijing) Co Total Receivables Related Terms

Thank you for viewing the detailed overview of Biocytogen Pharmaceuticals (Beijing) Co's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Biocytogen Pharmaceuticals (Beijing) Co Business Description

Traded in Other Exchanges
Address
12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, CHN
Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma, and other advanced solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC), and other solid tumors.

Biocytogen Pharmaceuticals (Beijing) Co Headlines

No Headlines